INCY Incyte
- 67.490
- +0.450+0.67%
- 67.490
- 0.0000.00%
Incyte News
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Guggenheim Adjusts Price Target on Incyte to $86 From $92
Wolfe Research Initiates Incyte(INCY.US) With Buy Rating, Announces Target Price $84
Incyte Initiated With an Outperform at Wolfe Research
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
Is Incyte Stock Underperforming the Nasdaq?
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Incyte Corporation's (NASDAQ:INCY) Business And Shares Still Trailing The Industry
Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET
Express News | Incyte Corporation : Deutsche Bank Raises Target Price to $61 From $60
Express News | Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Downgraded at Truist on Jakafi Patent Cliff
Truist Financial Downgrades Incyte(INCY.US) to Hold Rating, Announces Target Price $74
Express News | Incyte : Truist Securities Cuts to Hold From Buy; Cuts Target Price to $74 From $83
JMP Securities Reiterates Market Perform on Incyte
Incyte's Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics
Incyte Closes 5% Higher Bolstered by Zynyz Data, Guggenheim Note
Analysis
Price Target
No Data
No Data
